Bavarian Nordic’s Post

View organization page for Bavarian Nordic, graphic

55,725 followers

Today, we announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) seeking approval of our vaccine candidate for immunization to prevent disease caused by #chikungunya virus infection in individuals 12 years of age and older. “The MAA marks our second major submission in just a few weeks as part of our efforts to launch the chikungunya vaccine next year in the U.S. and Europe. Chikungunya, like other mosquito-borne infectious diseases, represents an increasing public health threat due to factors such as climate-change, but also resulting from improved disease surveillance and diagnosis. Our vaccine candidate is designed for ease of use in individuals 12 years of age and older at risk of chikungunya virus and represents an important contribution to the development of preventative solutions against this debilitating disease,” said Paul Chaplin, President and CEO of Bavarian Nordic. Read more: https://lnkd.in/dcBEp5jg

  • No alternative text description for this image
Gwénaëlle Nivollet

Stability program manager and SME molecular biology at Bavarian Nordic

3mo

Proud to be part of it!

Alex Cooper

Recruitment Consultant | Drug Safety | Barrington James

3mo

Very exciting news!

Dmitri Nikoulitchev, PhD/PharmD

Business Development Executive DARP at GenScript. 8500 +

3mo

Great job, dear partners!

See more comments

To view or add a comment, sign in

Explore topics